Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent’s zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by “unprecedented” durability and tolerability-attributes that have limited the commercial success of other ROS1 agents, the analyst tells investors in a research note. Leerink believes the drug has the potential to be a blockbuster in ROS1+ tumors across all lines of therapy.
Confident Investing Starts Here:
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NUVL:
Disclaimer & DisclosureReport an Issue
